Amgen reveals second round of layoffs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Updated: AppFolio hires new CEO
Goleta-based AppFolio is heading in a new direction after the company announced on March 2 that its board of directors has unanimously elected Shane Trigg as its new president and CEO effective immediately. Trigg succeeds Jason Randall, who served as president and CEO since 2017. AppFolio is a provider of cloud business management solutions for Read More →
Analyst remains confident in Inogen despite huge selloff
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Mercado: Santa Maria AgTech event highlights changes in industry
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Capsida furthers its deal with AbbVie
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind delivers record revenue
MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, delivered a record year for revenue behind its multiple products out in the market. Based in Westlake Village, MannKind generated revenue worth $99.7 million in 2022, up from $75.2 million in 2021. In the fourth quarter, revenue also shot up to $36 Read More →
Arcutis gearing up for active 2023
Arcutis Biotherapeutics generated sales from its first treatment during the fourth quarter of 2022, helping usher in a new era for the company. Based in Westlake Village, Arcutis recognized $3 million in revenue for the quarter that ended Dec. 31, all of it coming from its Zoryve cream aimed to treat plaque psoriasis. For the Read More →
